Dr. Lal Path Labs Ltd. has informed the Exchange about Presentation
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs filed its Q4 & FY25 earnings presentation on April 25, 2025. Q4 revenue grew 10.5% YoY to Rs. 603 crore, with EBITDA up 16.9% to Rs. 169 crore. Reported Q4 PAT surged 81.4% to Rs. 156 crore, boosted by a one-time Rs. 41 crore deferred tax gain from the voluntary liquidation of subsidiary SDIPL; normalised PAT grew 33.8% to Rs. 115 crore. For full-year FY25, revenue rose 10.5% to Rs. 2,461 crore, EBITDA grew 14.2% to Rs. 696 crore, and normalised PAT climbed 24.6% to Rs. 451 crore. The company declared a 240% dividend, added 18 new labs (total 298), expanded PSCs to 6,607, and ended the year with a net cash position of Rs. 1,229 crore. Margins expanded meaningfully — EBITDA margin from 27.4% to 28.3% and PAT margin from 16.3% to 20.0% — driven by volume growth, favourable test and geographic mix, and operating leverage without any price hikes.
Strong margin expansion, volume-led growth without price hikes, and a robust net cash balance signal healthy fundamentals and potential for future reinvestment or shareholder returns. The 240% dividend payout is a positive for income-focused investors, though the headline Q4 PAT figure flatters underlying growth due to the one-time tax item.